ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Regulatory news

EU · EU licence (European Commission)

Teprotumumab (Tepezza)

Treatment of moderate to severe thyroid eye disease (TED).

CHMP opinion 25 Apr 2025 → EU licence 19 Jun 2025 · Amgen Europe B.V.

Research

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.